(1) Background: this research aims at studying the nephroprotective properties of BNO 2103 in a model of chromate-induced renal failure in rats and at proving the possibility of using BNO 2103 in clinical practice for the complex treatment of chronic kidney disease (CKD). (2) Methods: fifty rats divided into five groups were studied. The drugs BNO 2103, Prednisolone and Lespephril were administered within 20 days. The excretory function and the functional state of kidneys, blood biochemical parameters and indicators of nitrogen metabolism were determined. (3) Results: under the influence of BNO 2103, there was a significant improvement in renal excretory function, in nitrogen metabolism and blood biochemical parameters compared with the control pathology group. BNO 2103 also outperformed the comparators in most indicators. (4) Conclusions: BNO 2103 has demonstrated nephroprotective, hypoazotemic and diuretic effects; and can be used to implement to the combined therapy of CKD.

This research aims at studying the nephroprotective properties of BNO 2103 in a model of chromate-induced renal failure in rats and at proving the possibility of using BNO 2103 in clinical practice for the complex treatment of chronic kidney disease (CKD). Materials and methods. Fifty rats divided into five groups were studied. The drugs BNO 2103, Prednisolone and Lespephril were administered within 20 days. The excretory function and the functional state of kidneys, blood biochemical parameters and indicators of nitrogen metabolism were determined. Results. Under the influence of BNO 2103, there was a significant improvement in renal excretory function, in nitrogen metabolism and blood biochemical parameters compared with the control pathology group. BNO 2103 also outperformed the comparators in most indicators. Conclusions. BNO 2103 has demonstrated nephroprotective, hypoazotemic and diuretic effects; and can be used to implement to the combined therapy of CKD.

Management of chronic kidney disease is an urgent task of the global health care system, as untreated, it leads to partial or permanent loss of kidney function. Standardized herbal remedies are highly effective and relatively safe. That is why it is suggested to pay attention to herbal remedies already known for the treatment of genitourinary diseases to expand the indications for their use. The aim of the research is to study the nephroprotective properties of the standardized herbal composition BNO 2103, which is the active ingredient of Canephron N ®, in a model of renal failure in rats. Materials and methods. An experimental study was performed on 42 male white outbred rats weighing 150–200 g, which were divided into 4 groups. Nephropathy was induced by a single subcutaneous injection of 0.7 ml/kg of 2.5 % potassium chromate solution. Animals in 3 and 4 groups received BNO 2103 at a dose of 33.0 mg/kg and prednisolone at a dose of 1.9 mg/kg intragastrically daily for 20 days. After animals were sacrificed, their kidneys were obtained and studied with standard electronic microscopy methods. Results. BNO 2103 normalized the ultrastructural picture of the kidneys, however, with the presence of minor pathological signs. BNO 2103 reduced the destruction of basement membranes, improved organelle structure and increased metabolic processes in podocytes, and endotheliocytes, reducing the manifestations of degenerative-dystrophic changes in them. BNO 2103 was superior to the reference drug prednisolone. Conclusions. BNO 2103 showed a significant nephroprotective effect, normalizing the ultrastructural picture of the kidneys in rats with renal failure. This effect is most likely related to the presence of biologically active substances with a powerful antioxidant, anti-inflammatory, nephroprotective activity. The obtained results allow us to consider BNO 2103 as a promising nephroprotective agent for the treatment of chronic kidney disease.

Kidney and urinary tract diseases play an important role in the disease distribution in most countries of the world. The pharmaceutical industry offers many means for the treatment and prevention of these diseases, but there is a trending tendency to pay more attention to herbal medicines, their empirical application and scientific study. The aim of this research is to study anti-inflammatory properties of standardized herbal composition BNO 2103 in a model of paw inflammation in rats caused by different phlogogens to justify the use of it in the treatment of chronic kidney disease (CKD). Materials and methods. The experimental study was performed using 90 male white outbreed rats weighing 150–200 g, which were divided into 3 series of 30 animals each, each series included 3 groups. Inflammation of the paw was induced by subplantar administration of phlogogens – zymosan, histamine and serotonin. The study agent and the reference drug, diclofenac sodium, were administered intragastrically (i. g.) once. Edema was observed and recorded, and anti-inflammatory activity (AIA) was assessed in 0.5, 1.0, 2.0, 3.0 and 6.0 hours after phlogogen injection. Results. BNO 2103 showed a remarkable anti-exudative effect in the model of zymosan and histamine edema, being significantly superior to diclofenac sodium. In the serotonin edema model, BNO 2103 was significantly superior to the comparator by the endpoints, showing the moderate but prolonged anti-exudative effect. Conclusions. BNO 2103 has the significant anti-inflammatory effect, exerting an inhibitory effect on exudative inflammation caused by various phlogogens (zymosan, histamine, serotonin), mainly acting on the lipoxygenase pathway of arachidonic acid conversion, which is most likely due to the presence of flavonoids. This allows us to consider BNO 2103 as a promising drug for the treatment of CKD.